Inserm
Business Services · France · 10K+ Employees
View Company Info for Free
Overview
Headquarters
101 Rue De Tolbiac, Paris, Ile-de-France...Phone Number
+33 144236000Website
www.inserm.frRevenue
$1.3 BillionIndustry
About Inserm
Inserm Org Chart
Chef De Projet
Attaché De Recherche
Chercheur
Postdoctoral Researcher
Jeune Chercheur
Researcher
Doctoral Researcher
Researcher Phd Candidate
Research Fellow
Is Inserm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Inserm is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Inserm
Earning: See what the market has to say on Inserm recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Inserm had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Inserm has new funding data
Inserm, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Inserm launches new products
Check if Inserm has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Inserm
Find more new buyers
Company Profile Activity
Activity Insights
Inserm is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Inserm is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Inserm.
Inserm Tech Stack
A closer look at the technologies used by Inserm
Most Recent Scoops
Inserm News & Media
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio’s oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial in hospitalized COVID-19 patients. The EU-SolidAct trial (European DisCoVeRy for Solidarity: An Adaptive PandemicILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies today announced that the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) has selected ILiAD’s B-Tech Vector Technology for funding as part of its newly created Innovation for Tuberculosis Vaccine Discovery (ITVD) program. This program supports novel innovative vaccine candidates for the prevention of tuberculosis. According to the NIH grant funding opportunity announcement, “the WHO estNovoBiome and Inserm form new collaboration to simulate human intestinal physiology
NovoBiome and Inserm form new collaboration to simulate human intestinal physiologyBerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients. The EU-SolidAct trial - European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial - is part of EU-RESPONSE, a
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inserm
Inserm is a public scientific and technological establishment placed under the dual supervision of the Ministry of Health and the Ministry of Research. Dedicated to biological, medical and human health research, it is positioned on the entire route from the research laboratory to the patient's bed.... Read More